Tecfidera

E25438

Tecfidera is an oral disease-modifying medication used to treat relapsing forms of multiple sclerosis by reducing inflammation and relapse frequency.


Statements (48)
Predicate Object
instanceOf disease-modifying therapy
multiple sclerosis medication
pharmaceutical drug
belongsToClass fumaric acid esters
immunosuppressive agents
hasActiveIngredient dimethyl fumarate
hasAdministrationFrequency twice daily
hasApprovalBy European Medicines Agency
Food and Drug Administration
surface form: "U.S. Food and Drug Administration"
hasATCCode L04AX07
hasChemicalFormula C6H8O4
hasCommonSideEffect abdominal pain
diarrhea
flushing
nausea
pruritus
rash
vomiting
hasContraindication known hypersensitivity to dimethyl fumarate
hasDosageForm delayed-release capsule
hasEffectOn absolute lymphocyte count
hasFDAApprovalYear 2013
hasGenericName dimethyl fumarate
hasInitialDose 120 mg twice daily
hasLegalStatus prescription-only
hasMaintenanceDose 240 mg twice daily
hasMechanismOfAction anti-inflammatory
immunomodulatory
hasMolecularWeight 144.13 g/mol
hasPregnancyCategory use only if potential benefit justifies potential risk
hasRouteOfAdministration oral
hasSeriousAdverseEffect liver injury
lymphopenia
progressive multifocal leukoencephalopathy
isManufacturedBy Biogen
isProdrugOf monomethyl fumarate
isTakenWith food
mayCause flushing mediated by prostaglandins
reduces magnetic resonance imaging lesion activity in multiple sclerosis
relapse frequency in multiple sclerosis
risk of disability progression in multiple sclerosis
requiresMonitoring liver function tests
lymphocyte count
targetsPathway Nrf2 pathway
treats active secondary progressive multiple sclerosis
clinically isolated syndrome
relapsing forms of multiple sclerosis
relapsing-remitting multiple sclerosis

Referenced by (2)

Full triples — surface form annotated when it differs from this entity's canonical label.

Biogen hasNotableDrug Tecfidera
Biogen hasProduct Tecfidera

Please wait…